JPL Wealth Management LLC Buys Shares of 39,493 Pfizer Inc. (NYSE:PFE)

JPL Wealth Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFEFree Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 39,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,137,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Carr Financial Group Corp increased its stake in Pfizer by 3.3% during the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares in the last quarter. Advisor OS LLC grew its holdings in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC raised its stake in Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 371 shares during the last quarter. Cairn Investment Group Inc. lifted its position in Pfizer by 5.4% during the 3rd quarter. Cairn Investment Group Inc. now owns 7,323 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 372 shares during the period. Finally, Monetary Management Group Inc. grew its stake in Pfizer by 1.0% during the 3rd quarter. Monetary Management Group Inc. now owns 38,651 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 375 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of Pfizer stock traded up $0.64 during mid-day trading on Wednesday, reaching $29.20. 29,229,239 shares of the stock traded hands, compared to its average volume of 42,373,320. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average of $27.22 and a 200 day moving average of $27.96. The stock has a market capitalization of $165.46 billion, a PE ratio of -485.42, a PEG ratio of 1.20 and a beta of 0.63. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the firm posted $1.23 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.75%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $35.86.

Check Out Our Latest Stock Analysis on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.